Agonist News and Research

RSS

Developing the Next Generation of Water-soluble DREADDs

An interview with James Flanaghan, discussing the uses of DREADDs in neurobiological research and the advantages of water-soluble ligands.

From Hello Bio 19 Dec 2018

Combination of a vaccine and checkpoint drugs reduces pancreatic tumors in mice

Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people with pancreatic cancers whose response to standard immunotherapy is poor.

18 Dec 2018

Innovative care model for children with ASD reduces use of behavioral drugs in ED

An innovative care model developed by Nemours Children's Hospital for children with autism spectrum disorders in the emergency department reduces the use of medication administered to kids who are prone to stress and sensory overload in this care setting.

11 Dec 2018

Experts address sleep disorders following traumatic brain injury

Disorders of sleep are some of the most common problems experienced by patients after traumatic brain injury. It is important to recognize and treat these problems early to allow for optimal cognitive recovery, but because they are so common, the importance of treating them is often underestimated.

10 Dec 2018

Liraglutide drug associated with lower risk of cardiovascular events

Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death.

6 Dec 2018

New study could provide a potential new drug to help fight obesity

Our bodies contain two types of fat: white fat and brown fat. While white fat stores calories, brown fat burns energy and could help us lose weight. Now, scientists at the University of Cambridge have found a way of making the white fat 'browner' and increasing the efficiency of brown fat.

27 Nov 2018

Food insecurity during pregnancy linked to severity of neonatal abstinence syndrome

A new study shows that food insecurity in pregnant women being treated for opioid use disorder may be associated with increased risk for their infants receiving pharmacologic treatment for neonatal abstinence syndrome.

13 Nov 2018

New synthetic compound based on brain hormone holds promise for cancer treatment

A lab team led by Nobel Prize winner Dr. Andrew Schally at the Miami Veterans Affairs Healthcare System and the University of Miami showed that a synthetic compound based on a brain hormone spurred the growth of cancer cells in Petri dishes but enigmatically had the opposite effect in mice.

6 Nov 2018

New discovery may unlock development of next-generation sleeping pill

Insomnia is one of the major sleep problems with an estimated prevalence of 10% to 15% in the general population and 30% to 60% in the older population. Moreover, insomnia frequently co-occurs with a wide range of psychiatric disorders, including depression and anorexia.

26 Oct 2018

Drugs approved for breast cancer treatment are effective and well tolerated in men

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

23 Oct 2018

SLU researcher seeks to find solutions for 'chemo brain' symptoms and side effects of opioids

With a pair of RO1 grants from the National Institutes of Health, pain researcher Daniela Salvemini, Ph.D., will embark on two new research projects, studying chemotherapy-induced cognitive impairment, or "chemo brain," symptoms and unwanted side effects of opioids.

23 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich.

22 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Appetite-suppressant drug reduces diabetes risk and increases remission rates of blood sugar

New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Berlin, Germany, and published in The Lancet, shows that the appetite-suppressant drug lorcaserin decreases risk of developing diabetes and increases the rates of remission of high blood sugar.

4 Oct 2018

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

New research presented at the annual meeting of the European Association for the Study of Diabetes and published simultaneously in The Lancet Diabetes & Endocrinology shows how the glucose-lowering drug lixisenatide can slow or prevent damage to the kidneys in macro-albuminuric patients with type 2 diabetes mellitus and cardiovascular disease.

3 Oct 2018

Disruption in combination inhaled corticosteroid therapy may impact patients' symptoms and disease control

Disruption of the refill of patients' regular combination inhaled corticosteroid therapy brand may have impacted symptoms and disease control and potentially lead to an increased rate of costly exacerbations and hospitalizations.

2 Oct 2018

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

21 Sep 2018

Researchers develop new generation of pain medications

Researchers from Charité - Universitätsmedizin Berlin and the Zuse Institute Berlin have developed a new generation of pain medications.

7 Sep 2018

Shionogi launches Mulpleta in the U.S for safe, effective treatment of thrombocytopenia

Shionogi & Co., Ltd. announced today that Mulpleta (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure, is now available throughout the United States.

30 Aug 2018